Labcorp Holdings Inc.

Labcorp Holdings Inc.

LH

Get informed when a big investor buys or sells

+ Follow
Market Cap$25.35B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Labcorp Holdings Inc.Labcorp Holdings Inc.25.40.93%12%1.80.8

Earnings Call Q2 2026

July 30, 2026 - AI Summary

Solid Q2 results; margins & EPS up strongly - Revenue +6% to $3.7B; organic revenue +4.2% - Adjusted operating margin +70 bps to 15.8% - Adjusted EPS +15% to $4.99 - Free cash flow $314M (notably down vs prior year due to working capital timing and planned capex increases)
Diagnostics growth driven by specialty + higher tests per accession - Diagnostics revenue +$5.5% to $2.9B - Organic Diagnostics +3.6%, with volume +3% and price/mix +2.5% - Management emphasized continued specialty testing outgrowing routine testing and ongoing increases in “tests per accession” (supporting mix/price and volume momentum) - Also said ACA/Medicaid impact is not a big drag overall (details below)
BLS strong quarter; Early Development restructuring now largely “behind” - Biopharma Laboratory Services revenue +$6.5% to $836M - Book-to-bill: 1.14 (quarter) / 1.03 (TTM)—positive demand signal - Central Labs (majority of BLS) performing strongly: Central Labs +10% (reported) / ~+8% (organic constant currency) - Early Development: -1% reported, but +3% organic constant currency; benefits and margin expansion tied to strategic actions that are announced and largely complete

Exclusive for Stockcircle Pro members

Sign upSign Up
$325.00

Target Price by Analysts

5.1% upsideLabcorp Holdings Target Price DetailsTarget Price
$377.62

Current Fair Value

22.1% upside

Undervalued by 22.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$25.35 Billion
Enterprise Value$32.37 Billion
Dividend Yield$2.88 (0.93%)
Earnings per Share$10.54
Beta0.86
Outstanding Shares81,700,000

Return

Return on Equity11.65%ROE
Return on Assets5.41%
Return on Invested Capital9.78%

Valuation & Multiples

P/E Ratio25.41P/E Ratio
PEG99.41PEG
Price to Sales1.77Price to Sales
Price to Book Ratio2.94Price to Book Ratio
Enterprise Value to Revenue2.26
Enterprise Value to EBIT20.18
Enterprise Value to Net Income32
Total Debt to Enterprise0.22
Debt to Equity0.83Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 30, 2026
EPS Estimate
$4.78
Average shareholder expectation
Revenue Estimate
$3.71 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 27, 2026
EPS Estimate
$4.60
Average shareholder expectation
Revenue Estimate
$3.75 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 31.88%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %7.08%▼ 87.69%
Total Invested$1.59B▼ 92.36%
Investors Holding396▼ 636.00%

ESG Score

No data

About Laboratory Corp. Of America Holdings

CEO: David King

Relevant Senate Committees

Joint Committee on Taxation

Provides crucial analysis and scoring for all tax legislation, directly influencing corporate tax structures, capital investment credits, and the overall tax burden on the company.

Finance

Controls corporate taxation and trade policy (e.g., tariffs on imported materials), which directly impact profitability and supply chain costs for a manufacturing business like a dental lab.

Health, Education, Labor, and Pensions

Directly oversees the FDA (regulating medical devices and materials used in dental labs) and labor laws, significantly impacting manufacturing processes, material approvals, and operational costs.

Judiciary

Oversees antitrust and intellectual property law, which can directly affect mergers and acquisitions, and patent protection for dental technologies, materials, and processes crucial for a manufacturing lab.